PatientsVille.com Logo

ERYTHEMA and ALEVE

PatientsVille

ERYTHEMA Symptoms and Causes

Fifth disease is a viral infection caused by parvovirus B19. The virus only infects humans; it's not the same parvovirus that dogs and cats can get. Fifth disease mostly affects children. Symptoms can include a low fever, cold symptoms, and a headache. Then you get a red rash on your face. It looks like a "slapped cheek." The rash can spread to the arms, legs, and trunk. Adults who get it might also have joint pain and swelling.

Fifth disease spreads easily, through saliva and mucus. You can get it when an infected person coughs or sneezes. Frequently washing your hands might help prevent getting the virus. Most people become immune to the virus after having it once.

Fifth disease is usually mild and goes away on its own. However, it can be serious if you

  • Are pregnant
  • Are anemic
  • Have cancer or a weak immune system

Centers for Disease Control and Prevention

Check out the latest treatments for ERYTHEMA

ERYTHEMA treatment research studies

ALEVE clinical trials, surveys and public health registries


Find Drug Side Effect reports



ALEVE Side Effects

No Adverse Event (1413)
Nausea (722)
Dizziness (698)
Hypersensitivity (658)
Abdominal Pain Upper (643)
Pruritus (614)
Headache (536)
Dyspnoea (508)
Urticaria (487)
Arthralgia (429)
Abdominal Discomfort (394)
Blood Pressure Increased (383)
Vomiting (381)
Pain (349)
Swelling Face (339)
Dyspepsia (337)
Erythema (333)
Diarrhoea (315)
Back Pain (315)
Rash (305)
Oedema Peripheral (300)
Somnolence (299)
Insomnia (299)
Haematochezia (264)
Extra Dose Administered (263)
Fatigue (260)
Constipation (253)
Asthenia (237)
Incorrect Dose Administered (233)
Chest Pain (233)
Lip Swelling (222)
Feeling Abnormal (220)
Pain In Extremity (217)
Overdose (216)
Abdominal Pain (215)
Loss Of Consciousness (197)
Faeces Discoloured (181)
Throat Irritation (172)
Palpitations (160)
Eye Swelling (152)
Hyperhidrosis (141)
Arthritis (139)
Paraesthesia (138)
Contusion (133)
Feeling Hot (132)
Swollen Tongue (128)
Off Label Use (128)
Stomach Discomfort (125)
Rectal Haemorrhage (117)
Burning Sensation (116)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I took one Aleve at 3:30 PM and by 6:30 PM I had extreme abdominal pain lasting several hours and now the next day I still am uncomfortable. I will never take Aleve again!!

<span style='color: #808080;'><b>Describe Your Rash erythematous from DTAP (DAPTACEL) 2010 Experience Here:</b> <strong>My son 4 month, had an itchy redrash around his eyes and checks. Fever and Drowsy

After taking aleve i was taken to the emergency room with a servere case of cellulitus on my hand and in my nose. The swelling itching and blisters were absolutely horrible and this pain lasted for days even after taking antibiotics and even having a

AFTER TAKING TWO ALEVE PILLS, I WOKE UP WITHIN TWO HOURS ITCHING IN THE PALM OF MY HANDS FIRST, THEN ALL OVER MY BODY. RASHES APPEARED, SWELLING AND HEART BEATING VERY FAST. MY LIPS LOOKED LIKE I HAD BOTOX . AL

Constant/terrible diahria and voimiting and nausea

Dry mouth/thirst

Extream skin itching

Got rash on legs and buttocks after using Aleve. Not painful...what should I do? Of course I stopped using it.

Have 2 herniated discs and shoulder tendonitis. Aleve relived shoulder pain better than cortisone shot. Am concerned about effects on creatinine though as mine is high normal.

How long should i take aleve?

34YEARs old & suffer from erythema &use neotigason

Anyone else experiencing erythema multiforme minor from glipizide?

Hurricane spray pre endoscopy. Erythema and burning of gums, tongue and pharynx for several days. Little relief with cool water rinses.

I recently had an endoscopy and it showed in my stomach noted erythema and edema of the gastric mucosa. Multiple polyps all over the stomach. Snake-skin appearance of the gastric mucosa consistent with congestive gastropathy.&

Iam use neotigason because i suffer erythema

My son had a sore neck. I applied Bengay to massahe him. He started to feel an intense burn right away. The skin turned red like he had a bad sun erythema. I stopped immediately, washed the skin and put ice on his neck to ease the burning

Three months after second HPV, 14 year old female diagnosed with Erythema Nodosum affecting R shin with joint pain, no history of any health problems previous to this. Third dose administered 1 month after diagnosis (not thinking Vaccination was caus

ERYTHEMA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Antibiotic Treatment of Multiple Erythema Migrans
Condition: Multiple Erythema Migrans
Interventions: Drug: ceftriaxone;   Drug: doxycycline;   Other: Erythema migrans patients treated with doxycycline
Outcome Measures: Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple Erythema migrans with ceftriaxone or doxycycline for 15 days.;   Comparison of subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, or irritability between patients treated with antibiotic for multiple Erythema migrans and control subjects without a history of Lyme borreliosis.;   Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple Erythema migrans after antibiotic treatment.
2 Recruiting Cytokines and Chemokines in Erythema Migrans
Condition: Erythema Migrans
Intervention: Drug: antibiotic treatment
Outcome Measures: inflammatory proteins in Erythema migrans patients;   gene polymorphisms in Erythema migrans patients
3 Unknown  Affect of Dose Rate on UVR Induced Skin Erythema
Condition: Erythema
Intervention: Device: exposure to UVB radiation
Outcome Measure: To examine the difference in Erythemal response as a function of dose rate, and to assess the total amount of energy that is theoretically transmitted through a sunscreen within the range of SPF 2-10
4 Recruiting Doxycycline in Therapy of Erythema Migrans
Condition: Lyme Borreliosis
Intervention: Drug: Doxycycline
Outcome Measures: Comparing of objective sequelae and post-treatment subjective symptoms in three groups of Erythema migrans patients treated with doxycycline: with no accompanying symptoms, with mild and with severe symptoms at the beginning.;   Comparison of subjective symptoms between Erythema migrans patients treated with doxycycline and control subjects without a history of Lyme borreliosis.
5 Recruiting Analysis of Lyme Disease Lesions
Conditions: Erythema Migrans Lesions;   Erythema Migrans
Intervention:
Outcome Measure:
6 Not yet recruiting Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema
Condition: Erythema
Interventions: Drug: CD07805/47 Gel 0.5%;   Drug: CD07805/47 Gel Placebo
Outcome Measures: Composite success on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment);   Composite improvement on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment)
7 Not yet recruiting Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Conditions: Erythema;   Rosacea
Interventions: Drug: AGN-199201;   Drug: Vehicle to AGN-199201
Outcome Measures: Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales;   Percentage of Participants with at Least a 2-Grade Decrease from Baseline on SSA Using a 5-Point Scale;   Change from Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA);   Satisfaction Assessment for Rosacea Facial Redness Using a 5-Point Scale;   Symptom Assessment for Rosacea Facial Redness (Skin Sensation Domain Score) Using a 5-Point Scale;   Percentage of Participants with at Least a 1-Grade Decrease from Baseline on SSA Using a 5-Point Scale
8 Not yet recruiting Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Conditions: Erythema;   Rosacea
Interventions: Drug: AGN-199201;   Drug: Vehicle to AGN-199201
Outcome Measures: Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales;   Percentage of Participants with at Least a 2-Grade Decrease from Baseline on SSA Using a 5-Point Scale;   Change from Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA);   Satisfaction Assessment for Rosacea Facial Redness Using a 5-Point Scale;   Symptom Assessment for Rosacea Facial Redness (Skin Sensation Domain Score) Using a 5-Point Scale;   Percentage of Participants with at Least a 1-Grade Decrease from Baseline on SSA Using a 5-Point Scale
9 Not yet recruiting A Long-Term Safety and Efficacy Study of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Conditions: Erythema;   Rosacea
Intervention: Drug: AGN-199201
Outcome Measures: Percentage of Participants with Treatment-Related Adverse Events;   Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales
10 Recruiting An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
Condition: Papulopustular Rosacea
Interventions: Drug: Cromolyn Sodium;   Drug: Normal Saline
Outcome Measures: Facial Erythema;   Change in facial Erythema;   Matrix Metalloproteinase levels;   Change in matrix metalloproteinase levels
11 Unknown  Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness
Conditions: Telangiectasis;   Erythema
Interventions: Device: Pulsed dye laser;   Device: Intense pulsed light
Outcome Measure:
12 Recruiting Culture Media for Borrelia Burgdorferi Sensu Lato
Condition: Erythema Migrans
Interventions: Other: MKP media;   Other: BSK-H media
Outcome Measure: detection of Borrelia burgdorferi sensu lato by microscopy in dark field (positive vs. negative)
13 Recruiting A Study of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated With Aesthetic Procedures
Condition: Ecchymosis and Erythema Commonly Associated With Soft Tissue Filler Injections and Facial Ablative Laser Resurfacing Treatments.
Intervention: Dietary Supplement: Multizyme Cellular Vitality Cyruta Plus SHEP
Outcome Measures: Canfield Vectra Photography;   Heatherton & Polivy State Self-Esteem (HPSS) Scale, (SkinReplica) at Day 30 as compared to baseline (ablative laser group only, Global Aesthetic Improvement Scale (GAIS,
14 Unknown  Ciclosporin in the Management of New Erythema Nodosum Leprosum
Condition: Leprosy
Interventions: Drug: Ciclosporin;   Drug: prednisolone
Outcome Measures: time to relapse of ENL after initial control of symptoms;   time, in hours, to control initial episode of ENL relapse from time of starting anti-reactional medication;   time, in days, to ENL relapse from date of stopping anti-reactional medication
15 Unknown  Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum
Condition: Leprosy
Interventions: Drug: prednisolone;   Drug: ciclosporin
Outcome Measure:
16 Recruiting Photodynamic Therapy for Papulopustular Rosacea
Conditions: Rosacea;   Papulopustular Rosacea
Interventions: Drug: Aminolevulinic acid topical solution 20%;   Device: Blu-U Light Therapy
Outcome Measures: Improvement of the inflammatory lesions (papules, pustules, nodules), Erythema, and telangiectasia of rosacea as assessed by the Investigator's Global Assessment (IGA);   Improvement of the inflammatory lesions (papules, pustules, nodules) of rosacea as assessed by the Inflammatory Lesion Investigator's Global Assessment (ILIGA);   Evaluate improvement of rosacea associated Erythema as assessed by the Clinical Erythema Assessment (CEA) scale;   Evaluate improvement of the inflammatory lesions (papules, pustules, nodules) of rosacea as measured by a difference in inflammatory lesion count;   Evaluate improvement of rosacea as assessed by the Patient Overall Assessment Scale
17 Unknown  Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy
Conditions: Borderline Lepromatous Leprosy;   Lepromatous Leprosy
Interventions: Drug: Clofazimine;   Drug: Vitamin capsule
Outcome Measures: Incidence of ENL reactions;   Severity of ENL reactions
18 Unknown  Montelukast in ENL Reaction
Conditions: Erythema Nodosum Leprosum;   Leprosy
Intervention: Drug: montelukast in treatment of ENL reaction
Outcome Measures: decrease in ENL score;   absence of new nerve function impairment;   incidence of adverse effects
19 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
Outcome Measure: Enrichment of rare coding genetic variants
20 Recruiting Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea
Conditions: Erythematotelangiectatic Rosacea;   Rosacea
Intervention: Device: Ulthera System Treatment
Outcome Measures: Clinician Erythema Assessment at 90 days post-treatment compared to baseline;   CEA scale at 180 days post-treatment compared to baseline.;   CEA scale at 365 days post-treatment compared to baseline.;   Patient Self-Assessment (PSA) of Erythema at 90 Days compared to baseline.;   Patient Self-Assessment (PSA) of Erythema at 180 Days compared to baseline.;   Patient Self-Assessment (PSA) of Erythema at 365 Days compared to baseline.;   Dermatology Life Quality Index (DLQI) Assessment at 90 Days post-treatment;   Dermatology Life Quality Index (DLQI) Assessment at 180 Days post-treatment;   Dermatology Life Quality Index (DLQI) Assessment at 365 Days post-treatment;   Colorimeter at 90 Days post-treatment;   Colorimeter at 180 Days post-treatment;   Colorimeter at 365 Days post-treatment